✦ LIBER ✦

Stabilization of human papillomavirus virus-like particles by non-ionic surfactants

✍ Scribed by Li Shi; Gautam Sanyal; Alex Ni; Zheng Luo; Sarah Doshna; Bei Wang; Tammy L. Graham; Ning Wang; David B. Volkin

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 436 KB
Volume: 94
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.20377

No coin nor oath required. For personal study only.

✦ Synopsis

Human papillomavirus (HPV) virus-like-particles (VLPs) produced by recombinant expression systems are promising vaccine candidates for prevention of cervical cancers as well as genital warts. At high protein concentrations, HPV VLPs, comprised of the viral capsid protein L1 and expressed and purified from yeast, are protected against detectable aggregation during preparation and storage by high concentrations of NaCl. At low protein concentrations, however, high salt concentration alone does not fully protect HPV VLPs from aggregation. Moreover, the analytical analysis of HPV VLPs proved to be a challenge due to surface adsorption of HPV VLPs to storage containers and cuvettes. The introduction of non-ionic surfactants into HPV VLP aqueous solutions provides significantly enhanced stabilization of HPV VLPs against aggregation upon exposure to low salt and protein concentration, as well as protection against surface adsorption and aggregation due to heat stress and physical agitation. The mechanism of non-ionic surfactant stabilization of HPV VLPs was extensively studied using polysorbate 80 (PS80) as a representative non-ionic surfactant. The results suggest that PS80 stabilizes HPV VLPs mainly by competing with the VLPs for various container surfaces and air/water interfaces. No appreciable binding of PS80 to intact HPV VLPs was observed although PS80 does bind to the denatured HPV L1 protein. Even in the presence of stabilizing level of PS80, however, an ionic strength dependence of HPV VLP stabilization against aggregation is observed indicating optimization of both salt and non-ionic surfactant levels is required for effective stabilization of HPV VLPs in solution.

📜 SIMILAR VOLUMES

Disassembly and reassembly of yeast-deri

Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)

✍ Henryk Mach; David B. Volkin; Robert D. Troutman; Bei Wang; Zheng Luo; Kathrin U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB

The human papillomavirus (HPV) virus-like particles (VLPs) produced by recombinant expression systems are promising candidate vaccine antigens for prevention of cervical cancers as well as genital warts. However, expression of HPV type 6, 11, and 16 L1 proteins in Saccharomyces cerevisiae yielded ir

Presence of antibodies to human papillom

Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11–13-year-old schoolgirls

✍ Cubie, Heather A.; Plumstead, Michael; Zhang, Wei; de Jesus, Orlando; Duncan, Li 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

To allow meaningful approaches to vaccine development, it is important to know the extent of exposure to human papillomavirus (HPV) within the general population, and particularly the age at which the at risk population is infected. The humoral response to human papillomavirus is directed largely to

Electron Microscopic Evidence of Non-A,

Electron Microscopic Evidence of Non-A, Non-B Hepatitis Markers and Virus-Like Particles in Immunocompromised Humans

✍ Seishiro Watanabe; K. Rajender Reddy; Lennox Jeffers; Gordon M. Dickinson; Mark 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 633 KB

Characteristic pathological alterations of the liver in chimpanzees inoculated with non-A, non-B hepatitis sera have been described, but no corresponding findings have been reported in humans. Electron microscopic studies of the liver biopsy specimens of two homosexual patients with acquired immune

Modification of human papillomavirus-lik

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

✍ Kazunari Kondo; Hiroyuki Ochi; Tamae Matsumoto; Hiroyuki Yoshikawa; Tadahito Kan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

## Abstract Infection with human papillomavirus 16 (HPV16), which is one of the 15 types of HPV causally associated with cervical cancer and accounts for 50% of the cases, can be prevented in a type‐specific manner by an HPV16 virus‐like particle (VLP) vaccine comprised of particles of the L1 prote

Seroresponses to virus-like particles of

Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San People of Southern Africa

✍ Marais, Dianne; Rose, Robert C.; Lane, Christopher; Aspinall, Sanet; Bos, Pieter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

Virus-like particles (VLPs) of the high-risk human papillomavirus (HPV) types 16, 18, 31, 33, and 45 were used as antigen in enzyme-linked immunosorbent assay (ELISA) to determine the prevalence of serum IgG in a group of San people originally from Namibia, now residing in South Africa. The San chil

Immune response to human papillomavirus

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection

✍ Klaus Schäfer; Martin Müller; Stefan Faath; Annette Henn; Wolfram Osen; Hanswalt 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 146 KB 👁 1 views

Expression of human papillomavirus type 16 (HPV 16) fusion proteins LI deltaCE7(1-55) and LI deltaCE7(1-60) (carboxy-terminal deletion of LI replaced by 55 or 60 amino-terminal amino acids of E7) leads to formation of chimeric papillomavirus-like particles (CVLPs). After "infection" of cells by CVLP